RESUMO
Tumor-induced angiogenesis has been shown to suppress immune responses. One mechanism is to suppress leukocyte-endothelial cell interaction by down-regulating the expression of adhesion molecules, such as intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and E-selectin on the tumor endothelium, which enables tumor cells to escape immune surveillance. Calreticulin (CRT), a chaperone protein mainly located in the endoplasmic reticulum, has been shown to exert anti-angiogenic activity and inhibit tumor growth. Here, we demonstrate that in addition to inhibiting angiogenesis, CRT also enhances the expression of both ICAM-1 and VCAM-1 on tumor endothelial cells. This expression results in enhanced leukocyte-endothelial cell interactions and increased lymphocyte infiltration into tumors. Therefore, combining intramuscular CRT gene transfer with intratumoral cytokine gene therapies significantly improves the antitumor effects of immunotherapy by markedly increasing the levels of tumor-infiltrating lymphocytes. This combined treatment increased the levels of infiltrating lymphocytes to those achieved using four times the cytokine dosage. The combined therapy also resulted in lower levels of immunosuppressive molecules and higher levels of activated T-cells in the tumor microenvironment than immunotherapy alone. In conclusion, this study describes a new antitumor mechanism of CRT that involves the up-regulation of tumor endothelial adhesion molecules and the enhanced infiltration of tumor-specific lymphocytes. Thus, CRT treatment can make tumor cells more vulnerable to immunotherapy and improve the therapeutic efficacy of immunotherapy.
Assuntos
Calreticulina/metabolismo , Selectina E/metabolismo , Imunoterapia , Molécula 1 de Adesão Intercelular/metabolismo , Neoplasias Hepáticas Experimentais/imunologia , Neoplasias Hepáticas Experimentais/terapia , Molécula 1 de Adesão de Célula Vascular/metabolismo , Animais , Calreticulina/genética , Linhagem Celular , Linhagem Celular Tumoral , Proliferação de Células , Cricetinae , Selectina E/biossíntese , Selectina E/genética , Células Endoteliais/imunologia , Endotélio Vascular/imunologia , Endotélio Vascular/metabolismo , Técnicas de Transferência de Genes , Molécula 1 de Adesão Intercelular/genética , Leucócitos/imunologia , Ativação Linfocitária , Masculino , Camundongos , Camundongos Endogâmicos BALB C , NF-kappa B/metabolismo , Neovascularização Patológica , Ratos , Ratos Wistar , Linfócitos T/imunologia , Linfócitos T/metabolismo , Evasão Tumoral , Molécula 1 de Adesão de Célula Vascular/genéticaRESUMO
BACKGROUND: Ultrasound (US) is a novel and effective tool for the local delivery of genes into target tissues. US can temporarily change the permeability of a cell membrane and thus enhance the delivery of naked DNA into cells. In the present study, the efficiencies of gene expression mediated by US delivery in orthotopic liver tumor, subcutaneous tumor and muscle tissue were evaluated by changing the contrast agent concentrations and US exposure durations. METHODS: Plasmid DNA coding for luciferase, interleukin-12 or enhanced green fluorescence protein was mixed with SonoVue and injected intratumorally or intramuscularly. The injection sites were then exposed to US (20% duty cycle and 0.4 W/cm(2) intensity). RESULTS: The results obtained showed that the optimal condition was 50% SonoVue for tumors and 30% for muscle, with 10 min of US exposure. The expression levels of the transfected DNAs were in the order: muscle > subcutaneous tumor > orthotopic liver tumor. CONCLUSIONS: The present study indicates that muscle tissue is a good target site for producing large amounts of gene products for the purpose of gene therapy.